Centocor Inc, A Johnson & Johnson Company- Centocor utilizes cutting-edge knowledge in biotechnology to discover and develop innovative large and small molecule medicines. Centocor has a leadership position in monoclonal antibody technology. The company creates, acquires and markets unique biopharmaceutical therapies to aid patients in need. Centocor's innovative products focus on the management of three major disease areas; cardiovascular, immunologic disorders and cancer.
AGIL Analysis - Centocor
Integration
More emphasis on Direct Sales and Marketing
Low Cost Production
Targeted Markets and Products
Harmonization of processes and systems across all sites and R&D/Manufacturing
Take advantage of the Johnson and Johnson umbrella to achieve goals
Latent Values
Employees (Johnson & Johnson Credo)
Relationships with Customers/End Users (Doctors/Nurses) - (Johnson & Johnson Credo)
Compliance/Regulatory Profile with FDA and International Regulatory Agencies
Delivering Value to Customers
Goal Attainment
$4 Billion in Sales
Penetration; Gain Market Share
Customer Awareness
Cost Differentiation
Adaptation
Maintain capacity to meet anticipated demand for Rheumatoid Arthritis product, Remicade
Low Cost Strategy
Competitive Marketplace
Competitor Reactions
Capacity for Anticipated Demands
2. Amgen
Amgen has been successful in the first round of legal wrangling over a successfully keeping Transkaryotic Therapies (TKT) and its partner, Franco-German drug giant Aventis from marketing a drug similar to the highly profitable Epogen. Amgen's competition that includes Genentech, Chiron, Celera Genomics, Human Genome Sciences, Inc is not intense enough to reduce the amount of profits it takes in. The competition is still a factor but not as much. Amgen is a niche in the non-medically "necessary", but physiologically important medications, including endometriosis. The patients will gladly pay out of pocket for relief. Also, the fear of osteoporosis is enough for the population to pay high costs for any medication proven likely to forestall its consequences. Amgen's competitive strategy includes licensing agreements with competitors, including Johnson & Johnson,
Analysis
I think this analysis gives very thorough explanations of what each company does and plans to do. This would be very helpful to someone thinking of buying some biotech stock.
0 out of 0 people found this comment useful.